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Gender Differences in Health Status and Adverse Outcomes Among
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Background-—Few studies have examined gender differences in health status and cardiovascular outcomes in patients with
peripheral artery disease (PAD). This study assessed (1) self-reported health status at PAD diagnosis and 12-months later, and
explored (2) whether outcomes in women with PAD differ with regard to long-term major adverse events.
Methods and Results-—A total of 816 patients (285 women) with PAD were enrolled from 2 vascular clinics in the Netherlands.
Baseline clinical data and subsequent adverse events were recorded and patients completed the Short Form-12 (SF-12, Physical
Component Score [PCS] and Mental Component Score [MCS]) upon PAD diagnosis and 12-months later. Women had similar ages
and clinical characteristics, but poorer socio-economic status and more depressive symptoms at initial diagnosis, as compared
with men. Women also had poorer physical (PCS: 3710 versus 4010, P=0.004) and mental (MCS: 4712 versus 4911,
P=0.005) health status at the time of presentation. At 12-months, women still reported a poorer overall PCS score (4112 versus
4611, P=0.006) and MCS score (4214 versus 4912, P=0.002). Female gender was an independent determinant of a poorer
baseline and 12-month PCS and MCS scores. However, there were no signiﬁcant differences by gender on either mortality
(unadjusted hazard ratio [HR]=0.93, 95% CI 0.60;1.44, P=0.74) or major adverse events (unadjusted HR=0.90, 95% CI 0.63;1.29,
P=0.57), after a median follow-up of 3.2 years.
Conclusions-—Women’s physical and mental health status is compromised both at initial PAD diagnosis and at 12-month follow-up,
despite experiencing a similar magnitude of change in their health scores throughout the ﬁrst 12-months after diagnosis. ( J Am
Heart Assoc. 2014;3:e000863 doi: 10.1161/JAHA.114.000863)
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I n a recent scientiﬁc statement, the American HeartAssociation (AHA) released a “call to action” for more
focused care and research that is sensitive to the speciﬁc
concerns of women with peripheral artery disease (PAD).1
Until recently, the majority of data on gender-based differ-
ences has been derived from coronary artery disease (CAD)
where women have been shown to have poorer health status
outcomes,2 worse in-hospital/long-term mortality,3,4 and
increased mortality following cardiac revascularization proce-
dures.5 In contrast, major knowledge gaps exist in terms of
gender-speciﬁc differences in the health status of PAD and
cardiovascular mortality rates. Preliminary data suggest that
women with PAD suffer more from depression,6 experience
more atypical lower-extremity symptoms, have a poorer
overall health status (symptoms, functioning, quality of
life),7–15 and may be at increased risk for morbidity and
mortality as compared with men.16 Results from these studies
have been derived from small cohorts, cross-sectional work,
or studies that were not explicitly addressing gender differ-
ences in their primary objectives and analyses. With these
factors in mind, the current longitudinal study was designed
to assess gender-based differences in health status and long-
term adverse prognosis, including exploring the explanatory
role of depressive symptoms for these outcomes since
women are known to have worse depressive symptoms than
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men with PAD, and depressive symptoms have provided part
of the explanation for adverse outcomes in cardiovascular
disorders.6,17
In light of the above, the current study aimed to (1)
quantify self-reported symptomatic health status at PAD
diagnosis and 12-months later, and (2) explore whether
outcomes in women with PAD differ with regard to long-term
major adverse events (followed for a median of 3.2 years).
The underlying hypothesis was that women would have poorer
outcomes, including a poorer self-reported health status,
increased mortality, and an increased adverse event burden
as compared with men.
Methods
Participants
Participants with newly diagnosed symptomatic PAD or with
an exacerbation of existing PAD symptoms were consecu-
tively enrolled from 2 vascular outpatient clinics of the St.
Elisabeth Hospital (March 2006–November 2011) and Twee-
Steden Hospital (March 2006–October 2008) in Tilburg, the
Netherlands. Study entry criteria included having symptom-
atic PAD and an abnormal resting ankle–brachial index (ABI)
(≤0.90)18 or an abnormal postexercise ABI (ABI decrease of
15% following exercise). Exclusion criteria included critical leg
ischemia (we excluded patients in all Rutherford categories 4
to 6, which corresponds with the Fontaine III to IV classiﬁ-
cation),19 signiﬁcant cognitive impairment, severe psychiatric
co-morbidities, life-threatening or debilitating conditions that
prevented participation (eg, undergoing active cancer treat-
ment), and insufﬁcient knowledge of Dutch language and/or
illiteracy. Patients with a noncompressible ABI (≥1.30) were
also excluded. The protocol was approved by the local ethics
committees of the participating hospitals, and all participants
provided written informed consent. Patients were invited to
participate in the study by their treating vascular surgeon
during their visit at one of the outpatient clinics following a
vascular diagnostic work-up that conﬁrmed the presence of
PAD. All patients within the study completed a set of
questionnaires collected by mail following recruitment as
well as at 12-month follow-up. Demographic, risk factor,
medication, and therapeutic information was obtained by
abstracting patients’ medical records.
Measures
Health status
The Dutch version of the Short Form-12 (SF-12) was
administered to assess health status,20,21 both at PAD
diagnosis and 12-months later. This generic tool measures
overall physical and mental health status and consists of 12
items with standard Likert scales. Physical Component
Summary PCS and the Mental Component Summary MCS
scores22 are generated through a standardized scoring
algorithm and were based on weights derived from Dutch
population norms (score ranges between 0 and 100, mean
score=50, SD=10), with higher scores indicating better
functioning.23 Reference values in the overall population in
the Netherlands include a mean score of 518.9 and 528.4
for men on the MCS and PCS, respectively. Similarly, 499.6
and 49.389.7 represent the population averages for
women.23 The SF-12 has been demonstrated to be a valid
and reliable instrument20 and has been successfully utilized in
PAD populations.24,25
Depressive symptoms
The 14-item self-report Hospital Anxiety and Depression Scale
was used to measure self-reported depressive symptoms.
Criterion scores of ≥8 for the depression subscale denote
clinically relevant symptoms of depression.26,27
All-Cause Mortality and Adverse Events
The major adverse events studied included (1) all-cause
mortality and (2) acute myocardial infarction (AMI) that was
diagnosed by a cardiologist and required hospitalization, (3)
stroke that was diagnosed by a neurologist and required
hospitalization, and (4) any PAD-related lower-extremity
amputation (eg, amputation of toes or part of the foot, below
or above knee amputation, and through-knee amputation due
to PAD, excluding traumatic amputations). Mortality was used
both as a separate outcome of interest and also as a
combined end point with the other major adverse events.
Information on adverse events was documented from
patients’ medical records by a surgical fellow supervised by
2 vascular surgeons. For mortality, in-hospital mortality as
well as mortality events outside the hospital were docu-
mented as patients’ medical records are linked to the regional
Social Security death index of the Tilburg community; deaths
occurring outside the Tilburg community were reported by
patients’ general practitioners.
Ankle-Brachial Index
The vascular laboratory assessment procedures have been
described previously.28 In brief, a handheld Doppler ultrasonic
instrument was used to obtain systolic blood pressure
readings in the right and left brachial arteries, right and left
dorsalis pedis arteries, and right and left posterior tibial
arteries. The ABI at rest and after walking on a treadmill
(distance limited 1000 m) was obtained with the lower resting
ABI used in all analyses. In all patients, the pain-free walking
distance and the ABI index were measured as indices of
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severity of PAD, whereby the ABI is deﬁned as the ratio of the
ankle systolic blood pressure to the brachial artery systolic
blood pressure and has a normal resting value of 1.0.29 A
value of <0.90 has been shown to be highly sensitive to
detect PAD.30
Sociodemographics and Clinical Variables
Age and gender were abstracted from medical records, and
information on sociodemographics was self-reported by the
patients. These included marital status (not having a partner
versus having a partner), high school education or more (less
than high school education versus high school education or
more), and work status (active versus non-active working
status). Clinical variables for patients were obtained from
medical records at baseline and included the following:
cardiovascular risk factors (current smoking, hypercholester-
olemia, hypertension, diabetes mellitus, chronic heart fail-
ure), cardiovascular history (previous AMI, angina, coronary
artery bypass grafting, percutaneous coronary intervention,
stroke, and transient ischemic attack), co-morbidities (renal
dysfunction, chronic obstructive pulmonary disease, body
mass index [kg/m2], prior documented back pain, prior
documented knee/hip osteoarthritis, and depression) and
PAD clinical factors (resting and postexercise ABI and pain-
free walking distance [PFWD]). Medications that patients
were taking upon enrollment were abstracted from their
medical charts.
Statistical Analysis
Baseline characteristics were examined for the total sample
and compared between genders. In addition, baseline and 12-
month follow-up health status scores were examined for the
total population and stratiﬁed by gender. The Student t tests
and Wilcoxon tests were used for continuous variables and v2
tests or Fisher’s exact tests were used for categorical
variables, as appropriate.
For the health status analyses, 6 sets of median regression
models examined the relationship between gender, and
(1) baseline SF-12 health status scores (baseline PCS and
MCS), (2) 12-month SF-12 health status scores (12-month
PCS and MCS), and (3) SF-12 health status change scores
(12-month PCS/MCS scores minus baseline PCS/MCS
scores). Median regression was performed due to nonlinear
distributions of health status scores. The following variables
were sequentially entered into the models: demographics
(gender, age), socio-demographics (marital status, educational
level), and cardiovascular risk factors and cardiovascular
history (diabetes, current smoking, prior stroke, prior AMI,
heart failure, and renal dysfunction). In 3 exploratory steps,
depression was included into the model ﬁrst, and obesity
(body mass index ≥30 versus <30), chronic obstructive
pulmonary disease, back pain, knee/hip osteoarthritis, PFWD,
and ABI thereafter. Interaction terms between gender and
age, and between gender and depressive symptoms for SF-12
scores were evaluated, but not included in the ﬁnal models, as
these terms were not signiﬁcant in any of the analyses.
Missing SF-12 items were assumed to be missing at
random and handled by multiple imputation (mean of 5
iterations) if ≥75% of all items were complete at baseline and
12-months. The pooled estimates and 95% CI for the 5
imputed datasets were used. A comparison of baseline
characteristics was conducted for those who were included
in the SF-12 analyses (0% to 25% missing) versus those who
were eligible for inclusion but who were not in the SF-12
analyses (>25% missing). Baseline characteristics were similar
between these groups; however, patients not in the analyses
were more likely to be women (Cramer’s V=0.079) or smokers
(Cramer’s V=0.083) as compared with those who were
included in the SF-12 analyses (all effect sizes were very
small).
Two sets of Cox proportional hazards models were
constructed to examine the relationship between gender
and (1) all-cause mortality and (2) major adverse events
outcomes (ie, all-cause mortality, AMI, stroke, and lower-
extremity amputation). As our study was mainly powered to
evaluate unadjusted associations between gender and health
status outcomes, the following 2 multivariable Cox models (1
for all-cause mortality and 1 for major adverse events) were
only conducted for exploratory and hypothesis-generating
reasons. Both models were sequentially built including the
following variables: demographics (gender, age), and cardio-
vascular risk factors and cardiovascular history (diabetes
mellitus, current smoking, prior stroke, prior AMI, heart
failure, and renal dysfunction). Socio-economic factors (mar-
ital status, educational level) and depression were only added
as an exploratory last step. We assessed an interaction term
between gender and age for all-cause mortality and major
adverse cardiac event outcomes, but in both analyses the
interaction term was not signiﬁcant (P=0.72, P=0.49, respec-
tively) and thus was excluded from the ﬁnal model. All tests
were 2-tailed and a P<0.05 was considered statistically
signiﬁcant. All analyses were performed using SPSS 17.0 for
Windows (PASW Inc, Chicago, IL) and SAS Software version
9.2. (SAS Institute Inc, Cary, NC).
Results
Patient Characteristics
Baseline characteristics of the total sample (N=816) were
stratiﬁed by gender and are listed in Table 1. The mean age of
the total cohort was 65 years and 285 (35%) were women.
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Table 1. Baseline/12-Month Demographics for the Total Sample and Stratiﬁed by Gender
Total Sample (n=816) Men (n=531, 65%) Women (n=285, 35%) P Value
Socio-demographics
Age (mean years, SD, range) 65.3 (9.8, 37 to 92) 65.3 (9.6) 65.2 (10.2) 0.91
No partner (n, %) 175 (25.1) 75 (16.8) 100 (39.7) <0.0001
<High school education (n, %) 177 (25.6) 96 (21.5) 81 (32.9) 0.001
Non-active work status (n, %) 501 (74.4) 328 (73.9) 173 (75.5) 0.64
Cardiovascular risk factors
Current smoker (n, %) 406 (49.8) 259 (48.8) 147 (51.6) 0.45
Hypercholesterolemia (n, %) 548 (67.2) 358 (67.4) 190 (66.7) 0.83
Hypertension (n, %) 488 (59.8) 306 (57.6) 182 (63.9) 0.08
Diabetes mellitus (n, %) 196 (24.0) 128 (24.1) 68 (23.9) 0.94
Chronic heart failure (n, %) 41 (5.0) 27 (5.1) 14 (4.9) 0.91
Cardiovascular history
Myocardial infarction (n, %) 151 (18.5) 103 (19.4) 48 (16.8) 0.37
Angina (n, %) 124 (15.2) 86 (16.2) 38 (13.3) 0.28
Coronary artery bypass graft (n, %) 90 (11.0) 66 (12.4) 24 (8.4) 0.08
Percutaneous coronary intervention (n, %) 74 (9.1) 50 (9.4) 24 (8.4) 0.64
Stroke (n, %) 66 (8.1) 49 (9.2) 17 (6.0) 0.10
Transient ischemic attack (n, %) 76 (9.3) 53 (10.0) 23 (8.1) 0.37
Co-morbidities
Renal dysfunction (n, %) 73 (8.9) 56 (10.5) 17 (6.0) 0.029
COPD (n, %) 142 (17.4) 91 (17.1) 51 (17.9) 0.79
Body mass index (mean, SD) 26.8 (5.0) 26.8 (4.4) 26.7 (6.0) 0.82
Back pain (n, %) 126 (15.4) 76 (14.3) 50 (17.5) 0.22
Knee/hip osteoarthritis (n, %) 169 (20.7) 116 (21.8) 53 (18.6) 0.28
Depressive symptoms (n, %) 186 (27.0) 103 (23.4) 83 (33.2) 0.005
PAD clinical factors
Resting ABI (mean, SD) 65.7 (16.9) 66.1 (17.1) 65.0 (16.5) 0.35
Postexercise ABI (median, SD) 36.0 (19.5) 35.0 (19.4) 36.5 (19.8) 0.17
PFWD (meters, median, SD) 80.0 (140.5) 80.0 (143.4) 70.0 (133.5) <0.0001
Medications
Aspirin (n, %) 647 (79.3) 427 (80.4) 220 (77.2) 0.28
Statin (n, %) 672 (82.4) 431 (81.2) 241 (84.6) 0.23
Anticoagulants (n, %) 139 (17.0) 86 (16.2) 53 (18.6) 0.38
b-Blocker (n, %) 345 (42.3) 222 (41.8) 123 (43.2) 0.71
Calcium channel blocker (n, %) 186 (22.8) 128 (24.1) 58 (20.4) 0.22
ACE inhibitor (n, %) 257 (31.5) 179 (33.7) 78 (27.4) 0.06
Diuretics (n, %) 206 (25.2) 128 (24.1) 78 (27.4) 0.31
Nitrate (n, %) 77 (9.4) 48 (9.0) 29 (10.2) 0.60
Antiarrhythmics (n, %) 21 (2.6) 12 (2.3) 9 (3.2) 0.44
Antidepressants (n, %) 48 (5.9) 23 (4.3) 25 (8.8) 0.010
Anxiolytics (n, %) 34 (4.2) 12 (2.3) 22 (7.7) <0.0001
Hypnotics (n, %) 37 (4.5) 18 (3.4) 19 (6.7) 0.032
Continued
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Both men and women were similar in terms of age,
cardiovascular risk factors, medical history, and ABI values
(resting and postexercise); however, women were less likely
to be partnered, have completed high school education or
more, or suffer from renal dysfunction as compared with men.
In addition, women also had a signiﬁcantly shorter PFWD.
Women also had higher rates of depressive symptoms and
were more likely to be on antidepressants, anxiolytics, and
hypnotics as compared with men (Table 1).
In regards to functional performance status at 12-months,
there was no difference between sexes in ABI values and/or
the change in ABI from baseline. In addition, although women
had a lower 12-month PFWD than men, there was no
statistically signiﬁcant difference from baseline to 12-months
(Table 1).
Health Status Analyses
In the total sample, median physical health status (PCS)
improved from 3910 at baseline (mean=399) to 4311
(mean=419) at 12-month follow-up (median difference
2.610; P<0.0001) (mean difference=1.8410). Conversely,
median mental health scores (MCS) did not improve over 12-
months (4811 at baseline [mean=4510] and 4713
[mean=4210] at 12-months, median difference 0.610,
P=0.12) (mean difference=2.9611).
Women, as compared with men, had poorer median
physical (PCS: 3710 versus 4010, P=0.004) (mean=389
versus 409) and mental (MCS: 4712 versus 4911,
P=0.005) (mean=4310 versus 4610) baseline health
status scores upon being diagnosed with PAD (Figure 1).
At 12-month follow-up, women still reported a poorer
overall median PCS score (4112 versus 4611, P=0.006)
(mean=409 versus 429) and MCS score (4214 versus
4912, P=0.002) (mean=4110 versus 4310). Women and
men had similar improvement in their physical function over
12-months (3.211 versus 2.410) (mean=1.9310 versus
1.7910) and neither group experienced an improvement in
their mental health status (1.212 versus 0.68.8)
(mean=2.9410 versus 2.9710).
In terms of baseline PCS scores, there was a signiﬁcant
effect of female gender in the unadjusted model (female
b=2.76, 95% CI 5.06;0.46, P=0.019). When adjusting for
clinical factors (female b=2.70; 95% CI 5.23;0.16,
P=0.037) (adjusted step 4), depression (adjusted step 5)
(female b=2.17, 95% CI 4.28;0.06, P=0.044), and other
exploratory factors (obesity [body mass index ≥30 versus
<30], COPD, back pain, knee/hip osteoarthritis, adjusted step
6) (female b=2.13; 95% CI 4.17;0.09, P=0.041), the
association between female gender and lower physical health
status persisted (full-model results are presented in Table 2;
sequential modeling results in Table 3).
In terms of baseline MCS scores, there was a trend
towards women reporting a poorer mental health status at
initial PAD diagnosis as observed in the unadjusted model
(female b=2.29, 95% CI 4.98;0.40, P=0.10), which
became signiﬁcant after adjustment for age (female
b=2.95 95% CI 5.53;0.37, P=0.025). After full adjust-
ment, there was no statistically signiﬁcant effect of female
gender in this model (female b=1.08, 95% CI 3.45;1.29,
P=0.37) (Tables 2 and 3).
Table 1. Continued
Total Sample (n=816) Men (n=531, 65%) Women (n=285, 35%) P Value
Functional performance at 12-months
12-month ABI (mean, SD) 68.4 (21.2) 68.2 (21.0) 68.7 (21.8) 0.79
Difference 12-month ABI (mean, SD) 2.9 (19.9) 2.6 (19.2) 3.6 (21.3) 0.58
12-month PFWD (meters, median, SD) 320 (355.8) 350.0 (353.3) 280.0 (357.2) 0.008
Difference 12-month PFWD (meters, median, SD) 220.0 (352.8) 240.0 (355.4) 190.0 (344.5) 0.11
ABI indicates ankle-brachial index; ACE, angiotensin-converting enzyme; COPD, chronic obstructive pulmonary disease; PAD, peripheral artery disease; PFWD, pain-free walking distance.
Figure 1. Median PCS and MCS SF-12 summary
scores at baseline and 12-month follow-up strati-
ﬁed by gender (red circle, PCS women; red square,
MCS women; blue triangle, PCS men; blue diamond,
MCS men). MCS indicates mental component
score; PCS, physical component score; SF-12,
short form-12.
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In terms of physical health status at 12-month follow-up,
women tend to report a poorer physical health status
(unadjusted female b=3.89, 95% CI 7.21; 0.58,
P=0.023). This effect persisted when adjusting for age
(female b=3.90; 95% CI 6.75; 1.06, P=0.007), after
adding depression to the model (adjusted step 5) (female
b=3.35; 95% CI 6.34; 0.37, P=0.028), as well as PFWD
and ABI (female b=2.69; 95% CI 5.24; 0.15, P=0.039).
Table 2. Full Adjusted Model for the Association Between Gender and Baseline Health Status
SF-12 PCS at Baseline SF-12 MCS at Baseline
Estimate 95% CI P Value Estimate 95% CI P Value
Full model
Female gender 2.70 5.23; 0.16 0.037 1.08 3.45; 1.29 0.37
Age 0.15 0.00 to 0.31 0.052 0.12 0.00 to 0.23 0.045
No partner 1.47 4.10;1.17 0.28 3.74 6.58;0.90 0.010
<High school education 2.71 5.32;0.11 0.042 2.31 5.02; 0.41 0.10
Diabetes 2.54 5.15;0.07 0.06 3.27 6.25; 0.29 0.031
Smoking 1.59 0.63;3.81 0.16 0.74 3.16; 1.69 0.56
Prior stroke 4.35 7.89;0.80 0.016 2.42 6.99; 2.15 0.30
Prior AMI 2.04 4.81;0.73 0.15 1.24 1.88; 4.37 0.44
Heart failure 6.35 11.94;0.75 0.027 5.88 13.08; 1.32 0.11
Renal dysfunction 3.92 7.61;0.23 0.039 3.52 7.47;0.42 0.09
Regression coefﬁcients (B) and 95% CIs are presented. AMI indicates acute myocardial infarction; MCS, mental component summary score; PCS, physical component summary score.
Table 3. Unadjusted and Adjusted Association Between Gender and Baseline Health Status
SF-12 PCS at Baseline SF-12 MCS at Baseline
Estimate 95% CI P Value Estimate 95% CI P Value
Unadjusted
Female gender 2.76 5.06; 0.46 0.019 2.29 4.98; 0.40 0.10
Adjusted step 1*
Female gender 2.25 4.81; 0.31 0.09 2.95 5.53; 0.37 0.025
Adjusted step 2†
Female gender 9.83 4.95; 24.62 0.19 3.69 19.40; 12.01 0.66
Adjusted step 3‡
Female gender 1.47 4.00; 1.06 0.26 0.40 3.18; 2.38 0.79
Adjusted step 4§
Female gender 2.70 5.23; 0.16 0.037 1.08 3.45; 1.29 0.37
Adjusted step 5k
Female gender 2.17 4.28; 0.06 0.044 1.33 3.22; 0.56 0.17
Adjusted step 6¶
Female gender 2.13 4.17; 0.09 0.041 1.78 3.82; 0.27 0.09
Adjusted step 7#
Female gender 1.76 3.67; 0.15 0.07 1.36 3.21; 0.48 0.14
Regression coefﬁcients and 95% CIs are presented. MCS indicates mental component score, PCS, physical component score. The following covariates are sequentially included in the
adjusted models: *adjusted model 1, gender and age; †adjusted model 2, model 1 and gender 9 age; ‡adjusted model 3, model 1 and socio-demographics (no partner and <high school
education); §adjusted model 4, model 3, and clinical factors (diabetes, current smoking, prior stroke, prior acute myocardial infarction heart failure, and renal dysfunction). The exploratory
adjusted models include the following covariates: kexploratory adjusted model 5, model 4 and depression; ¶exploratory adjusted model 6, model 5 and co-morbidities (body mass index
≥30 kg/m2, chronic obstructive pulmonary disease, back pain, and hip/knee osteoarthritis); #exploratory adjusted model 7, model 6, pain-free walking distance and ankle brachial index.
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There was no effect of gender within the intermediate
adjusted steps for PCS scores at 12-month follow-up (fully
adjusted model presented in Table 4; sequential analyses in
Table 5).
With regard to patients’ mental health status at 12-month
follow-up, women reported a poorer mental health status
(unadjusted female b=4.66; 95% CI 8.55; 0.77,
P=0.019) and also following adjustment for age (female
Table 4. Full Adjusted Model for the Association Between Gender and 12-Month Health Status
SF-12 PCS at 12 Months SF-12 MCS at 12 Months
Estimate 95% CI P Value Estimate 95% CI P Value
Full model
Female gender 3.41 6.88; 0.07 0.06 4.10 7.84; 0.36 0.032
Age 0.11 0.28; 0.05 0.20 0.10 0.07; 0.26 0.24
No partner 2.60 7.11; 1.90 0.27 1.29 6.02; 3.43 0.59
<High school education 3.13 6.70; 0.43 0.09 3.76 7.35; 0.17 0.040
Diabetes 5.81 10.12; 1.51 0.008 5.25 9.12; 1.38 0.008
Smoking 1.19 2.07; 4.46 0.49 0.77 2.42; 3.97 0.64
Prior stroke 3.54 9.17; 2.09 0.22 0.12 6.85; 6.61 0.97
Prior AMI 1.89 5.29; 1.52 0.28 0.49 3.28; 4.26 0.80
Heart failure 0.57 9.70; 10.84 0.76 3.81 15.25; 7.64 0.51
Renal dysfunction 7.88 13.61; 2.16 0.008 5.06 9.71; 2.14 0.033
Regression coefﬁcients (B) and 95% CIs are presented. AMI indicates acute myocardial infarction; MCS, mental component summary score; PCS, physical component summary score.
Table 5. Unadjusted and Adjusted Association Between Gender and 12-Month Health Status
SF-12 PCS at 12-Months SF-12 MCS at 12-Months
Estimate 95% CI P Value Estimate 95% CI P Value
Unadjusted
Female gender 3.89 7.21; 0.58 0.023 4.66 8.55; 0.77 0.019
Adjusted step 1*
Female gender 3.90 6.75; 1.06 0.007 4.99 9.07; 0.91 0.017
Adjusted step 2†
Female gender 9.53 30.03; 10.97 0.36 17.30 50.73; 16.14 0.31
Adjusted step 3‡
Female gender 2.32 5.95; 1.31 0.22 2.82 6.75; 1.11 0.16
Adjusted step 4§
Female gender 3.41 6.88; 0.07 0.06 4.10 7.84; 0.36 0.032
Adjusted step 5k
Female gender 3.35 6.34; 0.37 0.028 2.21 5.47; 1.05 0.19
Adjusted step 6¶
Female gender 2.26 5.05; 0.54 0.11 2.44 5.52; 0.65 0.12
Adjusted step 7#
Female gender 2.69 5.24; 0.15 0.039 1.04 4.35; 2.26 0.53
Regression coefﬁcients and 95% CIs are presented. MCS indicates mental component score; PCS, physical component score. The following covariates are sequentially included in the
adjusted models: *adjusted model 1; gender and age; †adjusted model 2, model 1 and gender 9 age; ‡adjusted model 3, model 1 and socio-demographics (no partner and <high school
education); §adjusted model 4, model 3 and clinical factors (diabetes, current smoking, prior stroke, prior acute myocardial infarction, heart failure, and renal dysfunction). The exploratory
adjusted models include the following covariates: kexploratory adjusted model 5, model 4 and depression; ¶exploratory adjusted model 6, model 5 and co-morbidities (body mass index
≥30 kg/m2, chronic obstructive pulmonary disease, back pain, and hip/knee osteoarthritis); #exploratory adjusted model 7, model 6, pain-free walking distance and ankle brachial index.
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b=4.99, 95% CI 9.07; 0.91, P=0.017) and clinical factors
(female b=4.10; 95% CI 7.84; 0.36, P=0.032) (adjusted
step 4 in the fully adjusted model).
Lastly, women’s 12-month change scores for physical and
mental health status did not differ signiﬁcantly from that of
men’s, neither in the unadjusted models for PCS (female
b=0.44, 95% CI 1.66; 2.54, P=0.68) and MCS (female
b=0.35, 95% CI 1.69;2.39, P=0.74), nor in the fully adjusted
models for PCS (female b=0.18, 95% CI 2.44; 2.08,
P=0.88) and MCS (female b=0.78, 95% CI 2.98; 1.43,
P=0.49) (Table 6 full-model results; sequential model results
are shown in Table 7).
Adverse Event Analyses
The study cohort had a median follow-up time of 3.2 years
(interquartile range=1.7 to 4.5 years). During follow-up, a
total of 92 (11%) deaths occurred (30 women [11%] versus 62
men [12%]) and 138 patients (17%) experienced a ﬁrst
adverse event (mortality, AMI, stroke, lower-extremity ampu-
tation) (45 women [16%] versus 93 men [18%]). The Kaplan–
Meier curves for all-cause mortality revealed no signiﬁcant
gender differences in survival time (P=0.74, Figure 2). Sim-
ilarly, for the onset of a ﬁrst adverse event (mortality, AMI,
stroke, lower-extremity amputation) there was no difference
between men and women (P=0.57, Figure 3).
No difference in all-cause mortality was observed between
men and women in the unadjusted (hazard ratio [HR] for
women=0.93, 95% CI 0.60;1.44, P=0.74) and the ﬁnal
adjusted model (HR=0.86, 95% CI 0.55; 1.34, P=0.50)
(Table 8). Older age (HR=1.05, 95% CI 1.02; 1.08, P<0.001),
current smoking (HR=1.57, 95% CI 1.00; 2.45, P=0.048),
heart failure (HR=3.27, 95% CI 1.80; 5.92, P<0.001), and
renal dysfunction (HR=1.90 95% CI 1.07; 3.39, P=0.030) were
independently associated with mortality in the ﬁnal adjusted
model (full model results are presented in Table 9).
Similar results were found for the association with adverse
events whereby men and women did not differ in both
the unadjusted (HR for women=0.90, 95% CI 0.63; 1.29,
P=0.57) and ﬁnal adjusted model (HR=0.85, 95% CI 0.59;
1.23, P=0.39). Again, older age (HR=1.06, 95% CI 1.04; 1.08,
P≤0.001), current smoking (HR=1.59, 95% CI 1.10; 2.30,
P=0.013), prior AMI (HR=1.72, 95% CI 1.18; 2.52, P=0.005),
and heart failure (HR=2.04, 95% CI 1.19; 3.49, P=0.010) were
independently associated with experiencing a ﬁrst adverse
event in the ﬁnal adjusted model (Table 9). Adding marital
status, educational level, and depression to the models did
not signiﬁcantly alter the results of the event analyses
(Table 10).
Discussion
This study is the ﬁrst of which we are aware to prospectively
compare women’s and men’s outcomes following their
diagnosis of PAD in a real-world setting. Since little is known
about the existence of potential gender disparities in PAD, the
AHA issued a scientiﬁc statement prioritizing a research
agenda for this important topic.1 Our study showed that there
were differences at both presentation and follow-up in terms
of health status, with women generally reporting worse
scores as compared with men. Demographic and clinical
factors were not always able to explain these differences in
Table 6. Full Adjusted Model for the Association Between Gender and Health Status Change Scores
SF-12 PCS Change Scores SF-12 MCS Changes Scores
Estimate 95% CI P Value Estimate 95% CI P Value
Full model
Female gender 0.18 2.44; 2.08 0.88 0.78 2.98; 1.43 0.49
Age 0.16 0.28; 0.04 0.011 0.01 0.09; 0.10 0.89
No partner 0.13 2.57; 2.31 0.86 1.79 0.50; 4.08 0.13
<High school education 1.09 3.05; 0.87 0.28 0.16 2.22; 1.90 0.85
Diabetes 1.33 4.18; 1.53 0.36 0.26 2.07; 2.59 0.82
Smoking 1.07 1.12; 3.26 0.34 0.70 0.86; 2.27 0.39
Prior stroke 0.84 3.98; 5.67 0.73 3.26 1.84; 8.36 0.21
Prior AMI 0.07 2.26; 2.39 0.96 0.51 3.12; 2.10 0.70
Heart failure 6.06 0.39; 11.73 0.045 0.01 5.33; 5.35 0.96
Renal dysfunction 3.67 7.77; 0.44 0.08 3.83 8.69; 1.04 0.14
Regression coefﬁcients (B) and 95% CIs are presented. AMI indicates acute myocardial infarction; MCS, mental component summary score; PCS, physical component summary score.
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our multivariable models. More objective performance mea-
sures and changes over 12-months in those measures such
as the ABI did not show any differences between men and
women, although women had a slightly lower threshold to
report pain when doing the treadmill exercise test (women
had lower PFWD scores as compared with men). The
magnitude of change in women’s health status scores over
Table 7. Unadjusted and Adjusted Association Between Gender and Health Status Change Scores
SF-12 PCS Change Scores SF-12 MCS Change Scores
Estimate 95% CI P Value Estimate 95% CI P Value
Unadjusted
Female gender 0.44 1.66; 2.54 0.68 0.35 1.69; 2.39 0.74
Adjusted step 1*
Female gender 0.74 3.46; 1.97 0.59 0.26 1.63; 2.14 0.79
Adjusted step 2†
Female gender 4.25 21.22; 12.72 0.63 9.57 21.62; 2.48 0.12
Adjusted step 3‡
Female gender 0.09 2.85; 3.03 0.82 0.77 2.66; 1.13 0.44
Adjusted step 4§
Female gender 0.18 2.44; 2.08 0.88 0.78 2.98; 1.43 0.49
Adjusted step 5k
Female gender 0.16 2.48; 2.15 0.89 0.57 2.79; 1.65 0.62
Adjusted step 6¶
Female gender 0.53 3.35; 2.30 0.71 0.30 2.14; 2.74 0.81
Adjusted step 7#
Female gender 0.67 2.00; 3.35 0.62 0.66 1.62; 2.94 0.56
Regression coefﬁcients and 95% CIs are presented. MCS indicates mental component score; PCS, physical component score. The following covariates are sequentially included in the
adjusted models: *adjusted model 1, gender and age; †adjusted model 2, model 1 and gender 9 age; ‡adjusted model 3, model 1 and socio-demographics (no partner and <high school
education); §adjusted model 4, model 3 and clinical factors (diabetes, current smoking, prior stroke, prior acute myocardial infarction, heart failure, and renal dysfunction). The exploratory
adjusted models include the following covariates: kexploratory adjusted model 5, model 4 and depression; ¶exploratory adjusted model 6, model 5 and co-morbidities (body mass index
≥30 kg/m2, chronic obstructive pulmonary disease, back pain, and hip/knee osteoarthritis); #exploratory adjusted model 7, model 6, pain-free walking distance and ankle brachial index.
Figure 2. Kaplan–Meier survival curve for all-cause 3.2 year
(interquartile range 1.7 to 4.5 years) mortality stratiﬁed by
gender. The P-value for the log rank test for women versus men is
provided (women, red line; men, blue line).
Figure 3. Kaplan–Meier survival curve for experiencing a ﬁrst
cardiovascular event (all-cause mortality, AMI, stroke, and lower-
extremity amputation) stratiﬁed by gender. The P-value for the log
rank test for women versus men is provided (women, red line;
men, blue line). AMI indicates acute myocardial infarction.
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12-months was also not different from that of men,
suggesting that both men and women improved equally
following PAD diagnosis and management. Importantly, health
status change scores for both men and women failed to reach
the threshold for what is deﬁned as a clinically relevant
difference (a clinically relevant difference is deﬁned as a
score of ≥5 to 10 for a 0.5 to 1.0 SD change, respectively) for
the SF-12. In addition, all mean health status scores at all
time points and across genders were far below the norm of
what is noted in the general Dutch population.8,23,31–34 This
underscores the need for more effective PAD management
strategies to alleviate the health status burden of PAD
patients in both men and women. Although multivariable
regression analyses adjusting for a broad range of potentially
confounding characteristics attenuated differences that were
found, the nature of the association remained the same. With
regard to our secondary aim, we were able to demonstrate
that survival/cardiovascular morbidity outcomes 3 years
following initial PAD diagnosis do not seem to differ between
genders, which was surprising considering the poorer prog-
nostic outcomes in women with CAD.4,35,36 These ﬁndings
may open opportunities to start looking into gender-based
interventions to improve health status, which have been
shown to be effective in CAD populations, including group-
based psychosocial interventions (ie, relaxation training
techniques, self-monitoring, and cognitive restructuring),
Table 8. Unadjusted and Adjusted Cox Proportional Regression Model Between Gender for Mortality and All-Cause Adverse
Events (Mortality, AMI, Stroke, and Lower-Extremity Amputation)
Mortality Adverse Events
HR 95% CI P Value HR 95% CI P Value
Unadjusted
Female gender 0.93 0.60; 1.44 0.74 0.90 0.63; 1.29 0.57
Adjusted 1
Female gender 0.90 0.58; 1.39 0.63 0.87 0.61; 1.24 0.43
Adjusted 2
Female gender 0.86 0.55; 1.34 0.50 0.85 0.59; 1.23 0.39
Hazard ratios (HR) and 95% CIs are presented. AMI indicates acute myocardial infarction.
Table 9. Unadjusted and Fully Adjusted Multivariable Cox Proportional Regression Model for Mortality and All Cause Adverse
Events (Mortality: AMI, Stroke, and Lower-Extremity Amputation)
Mortality Adverse Events
HR 95% CI P Value HR 95% CI P Value
Unadjusted
Female gender 0.93 0.60; 1.44 0.74 0.90 0.63; 1.29 0.57
Adjusted step 1
Female gender 0.90 0.58; 1.39 0.63 0.87 0.61; 1.24 0.43
Age 1.05 1.03; 1.08 <0.001 1.06 1.04; 1.08 <0.001
Adjusted step 2
Female gender 0.86 0.55; 1.34 0.50 0.85 0.59; 1.23 0.39
Age 1.05 1.02; 1.08 <0.001 1.06 1.04; 1.08 <0.001
Diabetes 0.92 0.56; 1.49 0.72 0.98 0.67; 1.45 0.94
Current smoking 1.57 1.00; 2.45 0.048 1.59 1.10; 2.30 0.013
Prior stroke 0.74 0.32; 1.72 0.48 0.95 0.52; 1.75 0.87
Prior AMI 1.30 0.81; 2.10 0.28 1.72 1.18; 2.52 0.005
Heart failure 3.27 1.80; 5.92 <0.001 2.04 1.19; 3.49 0.010
Renal dysfunction 1.90 1.07; 3.39 0.030 1.53 0.93; 2.52 0.10
Hazard ratios (HR) and 95% CIs are presented. AMI indicates acute myocardial infarction.
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telephone-derived collaborative care, and centralized depres-
sion care via telephone or internet.37–39
Symptomatic Health Status
Findings from our study are in line with previous research
suggesting that women with PAD have a worse health
status and health-related quality of life as compared with
men,9,13–15,40 and contrasts with those that have found no
differences by gender.41–44 Using the SF-36, previous authors
have demonstrated that physical functioning and general
health were both signiﬁcantly lower for women,14 which was
consequently associated with greater mood disturbance than
in men with PAD.13 In addition, female gender adversely
impacts durability or quality of life following revascularization
for claudication or critical limb ischemia.40 Furthermore,
young women (<50 years) with PAD scored lower than age-
matched healthy controls on all health-related quality of life
domains on the Research and Development 36-Item Health
Survey (RAND-36) in a cross-sectional population-based
study.15 Finally, a mixed cohort of patients with PAD at
various disease stages conﬁrmed that women experience
worse physical health, greater disability, as well as poorer
overall health status many years after diagnosis.9 These
preliminary studies were limited either in terms of their small
sample size, their (cross-sectional) design, or did not explicitly
focus on gender in their main objectives.9 Accordingly, our
study has extended the literature with results on prospectively
Table 10. Exploratory Multivariable Cox Proportional Model for Mortality and All Cause Adverse Events (Death, AMI, Stroke, and
Amputation)
Mortality Adverse Events
HR 95% CI P Value HR 95% CI P Value
Unadjusted
Female gender 0.93 0.60; 1.44 0.74 0.90 0.63; 1.29 0.57
Adjusted step 1
Female gender 0.90 0.58; 1.39 0.63 0.87 0.61; 1.24 0.43
Age 1.05 1.03; 1.08 <0.001 1.06 1.04; 1.08 <0.001
Adjusted step 2
Female gender 0.86 0.55; 1.34 0.50 0.85 0.59; 1.23 0.39
Age 1.05 1.02; 1.08 <0.001 1.06 1.04; 1.08 <0.001
Diabetes 0.92 0.56; 1.49 0.72 0.98 0.67; 1.45 0.94
Current smoking 1.57 1.00; 2.45 0.048 1.59 1.10; 2.30 0.013
Prior stroke 0.74 0.32; 1.72 0.48 0.95 0.52; 1.75 0.87
Prior AMI 1.30 0.81; 2.10 0.28 1.72 1.18; 2.52 0.005
Heart failure 3.27 1.80; 5.92 <0.001 2.04 1.19; 3.49 0.010
Renal dysfunction 1.90 1.07; 3.39 0.030 1.53 0.93; 2.52 0.10
Adjusted step 3
Female gender 0.72 0.41; 1.25 0.24 0.70 0.45; 1.10 0.12
Age 1.04 1.01; 1.07 0.004 1.06 1.03; 1.08 <0.001
Diabetes 0.90 0.51; 1.58 0.72 0.99 0.63; 1.55 0.96
Current smoking 1.42 0.85; 2.36 0.18 1.54 1.02; 2.33 0.041
Prior stroke 0.93 0.40; 2.20 0.88 1.06 0.56; 2.02 0.85
Prior AMI 1.22 0.69; 2.15 0.50 1.56 1.01; 2.43 0.047
Heart failure 2.76 1.36; 5.58 0.005 1.77 0.95; 3.32 0.07
Renal dysfunction 2.03 1.06; 3.88 0.034 1.58 0.90; 2.77 0.11
No partner 1.67 0.97; 2.87 0.06 1.55 0.90; 2.77 0.050
Lower education 1.12 0.66; 1.88 0.68 0.96 0.63; 1.47 0.86
Depression 1.60 0.97; 2.63 0.06 1.60 1.06; 2.41 0.026
Hazard ratios (HR) and 95% CIs are presented. AMI indicates acute myocardial infarction.
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captured health status information in a large, homogeneous
PAD population before they started treatment, demonstrating
that women with PAD have a compromised health status both
around prognosis and 12-months after follow-up. The reason
for this gender disparity is likely to be multifactorial and
requires further evaluation.
Mechanisms for Poorer Health Status in Women
The potential mechanisms contributing to the observed
gender disparity in health outcomes may include differences
in socio-demographics, clinical characteristics, and psycho-
social factors. As age and cardiovascular risk proﬁles were
similar between genders in this speciﬁc cohort, and were
included as covariates in the models, it seems unlikely that
these explain the observed differences in health status.
Furthermore, there was no difference noted in disease
severity with which patients presented at diagnosis (as
assessed by the ABI), which contradicts prior assertions that
differences in disease severity may explain poorer health-
related quality of life for women.40
In terms of socio-demographic factors, women reported a
lower educational attainment compared with men, which may
make them more vulnerable in dealing with the many
challenges that a diagnosis and management of PAD brings
forth, potentially translating into poorer health status scores.
Secondly, women were less likely to have a partner, which may
decrease the “protective effect” that marriage is associated
with.45 In particular, lack of social support has been shown to
be a potent risk factor for womenwith CAD46,47 due to a greater
propensity to engage in unhealthy behaviors and thus may be
an important factor on women’s health status in this PAD
cohort. These surrogate markers of socio-economics (educa-
tion, relationship status) should remain the focus of future
research, as they have been able to explain many disparities in
outcomes among cardiovascular populations.46,47
At initial diagnosis, women were also more likely than men
to present with depressive symptoms, thus severely impact-
ing their well-being. This ﬁnding has been previously demon-
strated at diagnosis and long-term follow-up, speciﬁcally,
younger women with PAD are known to be at a higher risk of
depression than other gender age groups.6 Depressive
symptoms or “mood states” as well as a greater degree of
bodily pain may be associated with substantially compro-
mised functional status48 as well as a poorer prognosis,49
which ultimately has adverse effects on patients’ health
status.50,51 When we adjusted for depression scores, after
including other relevant demographic, socio-economic, and
cardiovascular risk factors, we found further attenuation in
the association between gender and health status for physical
health status at baseline. Future investigations should explore
this in a formal mediation analysis.
Mortality and Adverse Events
To complement our analyses on gender differences and health
status outcomes in PAD, we additionally explored the
association between gender and adverse events. Cardiovas-
cular mortality, all-cause mortality, and major adverse coro-
nary event rates by gender have not been well examined in
PAD population-based studies. The few data available suggest
that the relationship between ABI values, mortality (total,
cardiovascular), and major coronary events are in fact similar
between genders.16 In the recent AHA statement, 16
population-based studies were pooled to examine these
associations, which revealed that the relationship between
ABI values and total mortality, cardiovascular mortality,
and major cardiovascular events are similar in women and
men.1 Furthermore, the gender effects on survival following
lower-extremity PAD revascularization have been inconsis-
tent.1,52,53 In our study, with real-world patients recently
diagnosed with PAD, we failed to observe signiﬁcant gender
differences in survival or experiencing a ﬁrst adverse event
over time; however, future, more adequately powered studies
should continue to evaluate this effect as these ﬁndings
appear to be counterintuitive against ﬁndings in CAD, where
clear evidence for poorer prognostic outcomes in women is
available.4,35,36
Limitations
Some limitations of this study are apparent. First, only two
institutions were included in this study and therefore results
may only be generalizable to this type of setting. As a result
minority patient populations were, for example, not well
represented, and therefore, future replications of our work
including more diverse populations are certainly needed.
Second, although we adjusted for clinically important con-
founders in both the SF-12 regression models and Cox
regression models, the possibility of residual confounding
remains. Last, we did not utilize a disease-speciﬁc health
status instrument, which may have been more sensitive to
detected differences in the clinical manifestations of PAD to
patients. This should be the focus of future research.
Conclusions
In conclusion, this study has extended ﬁndings from earlier
studies demonstrating that women report a poorer physical
and mental health status both at initial diagnosis (baseline)
and 12-month follow-up.9,13–15,40 Second, women seem to
have a similar prognosis as examined for all-cause mortality or
the experience of a ﬁrst adverse event as compared with men.
Future studies should focus on re-examining these effects
using more sensitive disease-speciﬁc health status
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instruments and further exploring the role for socio-economic,
clinical, and psychological factors in diverse settings of
patients that may help explain these differences.
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